文献速递临床试验与 GCP

生酮饮食作为药物辅助治疗能否提高局部复发或转移性Her-2阴性乳腺癌患者的化疗敏感性并缩小靶病灶:一项随机对照试验的研究方案

Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-06-05

该随机对照试验计划在辽宁肿瘤医院招募518例局部复发或转移性Her-2阴性乳腺癌女性,随机分为伊立替康+生酮饮食组(n=259)与伊立替康+正常饮食组(n=259)。主要终点为伊立替康敏感性和靶病灶客观缓解率,次要终点包括生活质量评分(EORTC QLQ-C30)、无进展生存期、总生存时间、不良事件发生率和成本效果。

要点

  • 探讨生酮饮食联合伊立替康能否提高Her-2阴性转移性乳腺癌化疗敏感性。
  • 计划招募518例患者,随机1:1分为联合干预组和对照组。
  • 主要终点为伊立替康敏感性和靶病灶客观缓解率。

核心结论

  • 该试验旨在观察伊立替康联合生酮饮食能否促进局部复发或转移性Her-2阴性乳腺癌患者对化疗的敏感性并缩小靶病灶。

研究设计与样本

  • 随机对照试验,计划招募518例就诊于中国东北辽宁肿瘤医院的局部复发或转移性乳腺癌女性。
  • 所有患者随机分为联合干预组(n=259,伊立替康+生酮饮食)或对照组(n=259,伊立替康+正常饮食)。

关键数值与推荐

  • 主要终点为伊立替康敏感性和靶病灶客观缓解率。
  • 次要终点包括生活质量评分(EORTC QLQ-C30)、无进展生存期、总生存时间、不良事件发生率和成本效果。
  • 终点评估时间为基线(给药前)、治疗期间、治疗完成后4周以及治疗完成后2个月起每3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have indicated that a ketogenic diet can be used as an adjuvant therapy to enhance sensitivity to chemotherapy and radiotherapy in cancer patients. However, there are no sufficient data and no consistent international treatment guidelines supporting a ketogenic diet as an adjuvant therapy for metastatic breast cancer. Therefore, this trial was designed to observe whether irinotecan with a ketogenic diet can promote sensitivity to chemotherapy and remit target lesions in locally recurrent or metastatic Her-2-negative breast cancer patients. METHODS/DESIGN: This trial aims to recruit 518 women with locally recurrent or metastatic breast cancer admitted to the Liaoning Cancer Hospital and Institute (Shenyang, China) in northeast China. All patients will be randomly assigned into the combined intervention group (n = 259) or the control group (n = 259), followed by treatment with irinotecan + ketogenic diet or irinotecan + normal diet, respectively. The primary endpoints are sensitivity to irinotecan and the objective response rate of target lesions; the secondary endpoints include quality of life scores (EORTC QLQ-C30), progression-free survival, overall survival time, incidence of adverse events, and cost-effectiveness. The endpoints will be evaluated at baseline (before drug administration), during treatment, 4 weeks after treatment completion, and every 3months (beginning 2 months after treatment completion). DISCUSSION: This trial attempts to investigate whether irinotecan treatment with a ketogenic diet for locally recurrent or metastatic breast cancer among women in northeast China can enhance the disease's sensitivity to chemotherapy and reduce target lesions. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR1900024597. Registered on 18 July 2019. Protocol Version: 1.1, 24 February 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang Y, Jing MX, Jiang L, et al. Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial. Trials. 2020. PMID: 32503654. doi:10.1186/s13063-020-04429-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。